Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly population

被引:2
|
作者
Sutandhio, Silvia [1 ]
Furukawa, Koichi [1 ]
Kurahashi, Yukiya [1 ]
Marini, Maria Istiqomah [1 ]
Effendi, Gema Barlian [1 ]
Hasegawa, Natsumi [1 ]
Ishimaru, Hanako [1 ]
Nishimura, Mitsuhiro [1 ]
Arii, Jun [1 ]
Mori, Yasuko [1 ]
机构
[1] Kobe Univ, Ctr Infect Dis, Div Clin Virol, Grad Sch Med, 7-5-1 Kusunoki Cho,Chuo Ku, Kobe, Hyogo 6500017, Japan
关键词
COVID-19; Elderly; Omicron; Vaccination; Neutralizing antibody; EXPRESSION; FUSION;
D O I
10.1016/j.jiph.2023.05.004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Omicron variants with immune evasion have emerged, and they continue to mutate rapidly, raising concerns about the weakening of vaccine efficacy, and the very elderly populations are vulnerable to Coronavirus Disease 2019 (COVID-19). Therefore, to investigate the effect of multiple doses of mRNA vaccine for the newly emerged variants on these populations, cross-neutralizing antibody titers were examined against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants, including BQ.1.1 and XBB. Methods: Blood samples were taken from residents at four long-term care facilities in Hyogo prefecture, Japan (median age, 91 years), after 3rd (n = 67) and 4th (n = 48) mRNA vaccinations, from April to October 2022. A live virus microneutralization assay was performed to determine the neutralizing antibody titers in participants' sera.Results: After 3rd vaccination, cross-neutralizing antibody prevalence against conventional (D614G) virus, Delta, Omicron BA.2, BA.5, BA.2.75, BQ.1.1, and XBB were 100%, 97%, 81%, 51%, 67%, 4%, and 21%, respectively. After 4th vaccination, the antibody positivity rates increased to 100%, 100%, 98%, 79%, 92%, 31%, and 52%, respectively. The 4th vaccination significantly increased cross-neutralizing antibody titers against all tested variants. Conclusion: The positivity rates for BQ.1.1 and XBB increased after 4th vaccination, although the titer value was lower than those of BA.5 and BA.2.75.Considering the rapid mutation of viruses and the efficacy of vaccines, it may be necessary to create a system that can develop vaccines suitable for each epidemic in consideration of the epidemic of the virus.(c) 2023 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:1064 / 1072
页数:9
相关论文
共 50 条
  • [1] Poor neutralizing antibody responses against SARS-CoV-2 Omicron BQ.1.1 and XBB in Norway in October 2022
    Vikse, Elisabeth Lea
    Fossum, Even
    Erdal, Magnhild Sekse
    Hungnes, Olav
    Bragstad, Karoline
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2023, 17 (06)
  • [2] An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB
    He, Qingwen
    Wu, Lili
    Xu, Zepeng
    Wang, Xiaoyun
    Xie, Yufeng
    Chai, Yan
    Zheng, Anqi
    Zhou, Jianjie
    Qiao, Shitong
    Huang, Min
    Shang, Guijun
    Zhao, Xin
    Feng, Youjun
    Qi, Jianxun
    Gao, George Fu
    Wang, Qihui
    CELL REPORTS MEDICINE, 2023, 4 (04)
  • [3] Defining a highly conserved cryptic epitope for antibody recognition of SARS-CoV-2 variants including the Omicron subvariants BQ.1.1 and XBB
    Li, Cheng
    Chen, Cuicui
    RESPIROLOGY, 2023, 28 : 221 - 221
  • [4] Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children
    Bellusci, Lorenza
    Grubbs, Gabrielle
    Sait, Shaimaa
    Yonker, Lael M.
    Randolph, Adrienne G.
    Novak, Tanya
    Kobayashi, Takuma
    Khurana, Surender
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [5] Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children
    Lorenza Bellusci
    Gabrielle Grubbs
    Shaimaa Sait
    Lael M. Yonker
    Adrienne G. Randolph
    Tanya Novak
    Takuma Kobayashi
    Surender Khurana
    Nature Communications, 14
  • [6] A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses
    Wang, Yingdan
    Hao, Aihua
    Ji, Ping
    Ma, Yunping
    Zhang, Zhaoyong
    Chen, Jiali
    Mao, Qiyu
    Xiong, Xinyi
    Rehati, Palizhati
    Wang, Yajie
    Wang, Yanqun
    Wen, Yumei
    Lu, Lu
    Chen, Zhenguo
    Zhao, Jincun
    Wu, Fan
    Huang, Jinghe
    Sun, Lei
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [7] Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants
    Bellusci, Lorenza
    Golding, Hana
    Khurana, Surender
    JOURNAL OF CLINICAL INVESTIGATION, 2023, 133 (08):
  • [8] Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1
    Miller, Jessica
    Hachmann, Nicole P.
    Collier, Ai-ris Y.
    Lasrado, Ninaad
    Mazurek, Camille R.
    Patio, Robert C.
    Powers, Olivia
    Surve, Nehalee
    Theiler, James
    Korber, Bette
    Barouch, Dan H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (07): : 662 - 664
  • [9] Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination
    Tauzin, Alexandra
    Benlarbi, Mehdi
    Medjahed, Halima
    Gregoire, Yves
    Perreault, Josee
    Gendron-Lepage, Gabrielle
    Gokool, Laurie
    Morrisseau, Chantal
    Arlotto, Pascale
    Tremblay, Cecile
    Kaufmann, Daniel E.
    Martel-Laferriere, Valerie
    Levade, Ines
    Cote, Marceline
    De Serres, Gaston
    Bazin, Renee
    Finzi, Andres
    VACCINES, 2023, 11 (02)
  • [10] Striking antibody evasion of SARS-CoV-2 Omicron sub-lineages BQ.1.1, XBB.1 and CH.1.1
    Ju, Bin
    Guo, Huimin
    Wang, Miao
    Fan, Qing
    Shen, Senlin
    Liao, Xuejiao
    Jiang, Jie
    Wang, Haiyan
    Wang, Fuxiang
    Zhang, Zheng
    NATIONAL SCIENCE REVIEW, 2023, 10 (08)